Comparative thermal and thermodynamic study of DNA chemically modified with antitumor drug cisplatin and its inactive analog transplatin

2014 ◽  
Vol 137 ◽  
pp. 85-93 ◽  
Author(s):  
Dmitri Y. Lando ◽  
Chun-Ling Chang ◽  
Alexander S. Fridman ◽  
Inessa E. Grigoryan ◽  
Elena N. Galyuk ◽  
...  
Keyword(s):  
Antitumor Drug ◽  
Thermodynamic Study ◽  
Chemically Modified ◽  
Inactive Analog

Adsorption of methylene blue on chemically modified lychee seed biochar: Dynamic, equilibrium, and thermodynamic study

2020 ◽  
Vol 315 ◽  
pp. 113743 ◽  
Author(s):  
Sumanta Sahu ◽  
Souman Pahi ◽  
Sujata Tripathy ◽  
Satish Kumar Singh ◽  
Abhijit Behera ◽  
...  
Keyword(s):  
Methylene Blue ◽  
Dynamic Equilibrium ◽  
Thermodynamic Study ◽  
Chemically Modified

Kinetic and thermodynamic study of a chemically modified highly active xylanase fromScopulariopsis sp

2007 ◽  
Vol 141 (2-3) ◽  
pp. 273-297 ◽  
Author(s):  
◽  
Ahmed Jawaard Afzal ◽  
Saleem Ahmed Bokhari ◽  
Khawar Sohail Siddiqui
Keyword(s):  
Thermodynamic Study ◽  
Chemically Modified ◽  
Highly Active ◽  
Kinetic And Thermodynamic Study

Radical chemistry of the antitumor drug pazelliptine (PZE) in aqueous solution or intercalated in poly(dA)-poly(dT)

1996 ◽  
Vol 93 ◽  
pp. 194-202
Author(s):  
E Renault ◽  
MP Fontaine-Aupart ◽  
M Gardès-Albert ◽  
C Rivalle ◽  
E Bisagni
Keyword(s):  
Aqueous Solution ◽  
Antitumor Drug ◽  
Radical Chemistry

Binding of Tissue Plasminogen Activator to Vascular Grafts

1989 ◽  
Vol 61 (01) ◽  
pp. 131-136 ◽  
Author(s):  
Richard A Harvey ◽  
Hugh C Kim ◽  
Jonathan Pincus ◽  
Stanley Z Trooskin ◽  
Josiah N Wilcox ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Fibrinolytic Activity ◽  
Polymer Surface ◽  
Enzymic Activity ◽  
Vascular Prostheses ◽  
Chemically Modified ◽  
Insoluble Surfactant ◽  
Tissue Plasminogen

SummaryTissue plasminogen activator labeled with radioactive iodine (125I-tPA) was immobilized on vascular prostheses chemically modified with a thin coating of water-insoluble surfactant, tridodecylmethylammonium chloride (TDM AC). Surfactant- treated Dacron, polytetrafluoroethylene (PTFE), silastic, polyethylene and polyurethane bound appreciable amounts of 125I- tPA (5-30 μg 125I-tPA/cm2). Upon exposure to human plasma, the amount of 125I-tPA bound to the surface shows an initial drop during the first hour of incubation, followed by a slower, roughly exponential release with a t½ of appoximately 75 hours. Prostheses containing bound tPA show fibrinolytic activity as measured both by lysis of clots formed in vitro, and by hydrolysis of a synthetic polypeptide substrate. Prior to incubation in plasma, tPA bound to a polymer surface has an enzymic activity similar, if not identical to that of the native enzyme in buffered solution. However, exposure to plasma causes a decrease in the fibrinolytic activity of both bound tPA and enzyme released from the surface of the polymer. These data demonstrate that surfactant-treated prostheses can bind tPA, and that these chemically modified devices can act as a slow-release drug delivery system with the potential for reducing prosthesis-induced thromboembolism.

Sign in / Sign up

Export Citation Format

Share Document